Emergent BioSolutions Inc. (EBS) on Monday announced a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the ASPR within the U.S. Department of Health and Human Services (HHS), to supply Tembexa oral suspension for the treatment of smallpox.
The contract follows the U.S. Food and Drug Administration's (FDA) recent approval to scale up production of Tembexa oral suspension.
This newly exercised contract modification for the supply of Tembexa builds on options announced in September 2024 under Emergent's 10-year agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.